

Management of Nausea and Vomiting in **Pregnancy and Hyperemesis Gravidarum**

This guideline is to support the management of people experiencing nausea and vomiting of pregnancy (NVP) and hyperemesis gravidarum (HG) in General Practice and specialist care settings in Sussex. It is based on The Royal College of Obstetricians and Gynaecologists guidance, The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum, where additional information can be found if required.

<u>1</u>	<u>Introduction</u>	2
2	Medication to manage symptoms of NVP and HG	3
3	Practice points for general practitioners	5
4	Practice points for Secondary Care (Inpatient Management)	6
<u>5</u>	Medication risk in pregnancy	8
<u>6</u>	Consideration of termination of pregnancy	9
7	How to refer for specialist support	9
8	Useful resources and Signposting information	9
APF	PENDIX 1. Summary for general practitioners	.10
APF	PENDIX 2. Summary for management in general practice	.11
APF	PENDIX 3. Summary for ambulatory care	.12
APF	PENDIX 4. Summary for emergency department staff	.13
APF	PENDIX 5. Summary for inpatient care	.13



1. INTRODUCTION

This guideline is based on The Royal College of Obstetricians and Gynaecologists (RCOG) guidance, <u>The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum</u>, where additional information can be found if necessary.

Nausea and vomiting of pregnancy (NVP) is defined as nausea and/or vomiting during pregnancy, when onset is prior to 16 weeks gestation and there are no other causes. NVP affects up to 90% of people during pregnancy and is one of the most common reasons for a hospital admission during pregnancy.

NVP is often referred to as morning sickness, which is inaccurate given symptoms do not only occur in the morning. It also trivialises the condition and should therefore be avoided.

Most pregnant people experiencing NVP can be successfully managed in General Practice. It is common for people with NVP to present to their GP because symptoms often occur prior to their pregnancy being booked by a midwife.

In many cases, people would have tried non-medical options to manage symptoms of NVP prior to presenting to a healthcare setting, therefore they may be experiencing severe symptoms at the point of first being seen by a GP.

Hyperemesis Gravidarum (HG) is a severe form of NVP, which affects up to 3.6% of pregnant people, significantly interfering with quality of life and the ability to eat and drink normally. HG can often be managed by GPs, but in some cases referral for specialist support, e.g., to Secondary Care or via the Maternal Medicine Centre, is necessary. The PUQE score [Appendix 2.] is used to differentiate NVP from HG.

NVP and HG are associated with serious health consequences for both mother and baby, especially if the mother is unable to take regular medication for a chronic health condition as a result. Prompt effective management of NVP and HG improves quality of life and pregnancy outcomes.



2. MEDICATION TO MANAGE SYMPTOMS OF NVP AND HG

- All the antiemetic medications included in this guideline can be taken in all trimesters of pregnancy. Information regarding risk of medication use in pregnancy can be found in section
 5.
- When managing pregnant people who experienced NVP or HG in a previous pregnancy, offer the medication that previously optimally managed their symptoms.
- When someone who is pregnant for the first time presents with NVP or HG, start treatment with either pyridoxine hydrochloride/doxylamine succinate (Xonvea), which is licensed for use in pregnancy, or cyclizine.
- Many people respond to pyridoxine hydrochloride/doxylamine succinate (Xonvea) when cyclizine has been ineffective.
- Combinations of antiemetics should be used in pregnant people who do not respond to a single agent, with some people requiring more than two medications to effectively manage their symptoms.
- Encourage use of antenatal vitamins at night to reduce possible influence on symptoms.
- Consider offering thiamine 100mg three times a day to patients with ≥13 PUQE score.

Pregnancy-Unique Quantification of Emesis (PUQE): a validated scoring system that may be used to assess the severity of symptoms of nausea and vomiting in pregnancy.

PUQE-24 scoring system

In the last 24 hours, for how long have you felt nauseated or sick to your stomach?									
Not at all (1) 1 hour or less (2) 2–3 hours (3) 4–6 hours (4) >6 hours (5)									
Not at all (1)									
In the last 24 hours	In the last 24 hours have you vomited?								
Did not throw up	5-6 times (4)	7 or more times (5)							
Did not throw up (1) 1-2 times (2) 3-4 times (3) 5-6 times (4) 7 or mor									
In the last 24 hours	In the last 24 hours how many times have you had retching or dry heaves without bringing anything								
up?									
No times (1)	1–2 times (2)	3-4 times (3)	5–6 times (4)	7 or more times (5)					

Total score indicating severity of symptoms is the sum of replies to each of the three questions: mild <= 6; moderate 7–12; severe 13–15. A score of 13 or greater has been used as a criterion for admission to hospital in women with severe nausea and vomiting of pregnancy.

General practitioners see Appendix 1 and 2
Secondary care practitioners see Appendix 3, 4, and 5

Advice available at all stages from the Sussex maternal medicine hub uhsussex.smmchelpline@nhs.net

STEP ONE

Doxylamine + pyridoxine (Xonvea) (only licensed product for use in pregnancy).

AND/OR

Cyclizine

STEP TWO

Combine regular use of a 1st line antiemetic with regular use of a 2nd line antiemetic (on dan setron / meto-clopramide / domperidone). Utilise synergistic effects of medications with different mechanisms of action

STEP THREE

Add an antiemetic with a different mechanism of action to regular use of 1st and 2nd line antiemetics AND refer to gynaecology /obstetrics (see section 7)

Admit to an ambulatory day unit for hydration and medication optimisation including administration of IV antiemetic medications. See section 4 for inpatient management.

Antiemetic*	Class	Preference	Tab.	Liq.	Oral Starting Dosing	lnj.	Other
Doxylamine + pyridoxine (Xonvea)	Antihistamine	1 ^{rt} line	x		TWO tablets to be taken at bed- time. Increase to additional ONE tablet in the morning and ONE tablet at lunch time if required.	х	
Cyclizine	Antihistamine		х	х	50 mg up to 3 times a day.		
Prochlorpera- zine	Phenothiazine	Other	Х		5 – 10 mg 2–3 times a day.	х	Buc- cal
Promethazine	Phenothiazine	1 ^{rt} line options	х		12.5 - 25 mg three to four times a day		
Ondansetron*	Serotonin antagonist		x	х	4mg three times a day or 8mg twice a day	х	Oro- disp.
Metoclopramide	Dopamine antagonist	2 nd or 3 rd line options	×	×	10 mg three times a day		
Domperidone	Dopamine antagonist		х	х	10 mg three times a day		

Ondansetron: Prescribe laxatives if constipation develops, if constipated at presentation consider a different 2nd line antiemetic. See section 5 for visualisation of cleft lip/palate incidence. Higher doses are possible discuss with uhsussex.smmchelpline@nhs.net

Doparmine antagonist and serotonin antagonists: Dosing duration limits are noted in product literature, but risks of longer-term prescribing need to be balanced against of unmanaged NVP or HG. RCOG states metoclopramide can be prescribed for more than five days during pregnancy when it alleviates symptoms. Patients must be counselled to stop medication immediately if they experience dystonic reactions.

See section 5 for Medication risk in pregnancy. Consult product literature for dosing and additional information to support safe prescribing



3. PRACTICE POINTS FOR GENERAL PRACTITIONERS

See Appendix 1 and Appendix 2

It is unusual for NVP or HG to start after 16 weeks of pregnancy, therefore alternative causes of symptoms should be considered, e.g. UTI, cholecystitis, infective gastroenteritis.

Assessment and monitoring

- Use the PUQE score to assess NVP or HG severity [Appendix 3]. Ketonuria is not an indicator of dehydration and should not be used to assess the severity of NVP or HG.
- Assess and regularly (e.g., weekly) monitor renal function, weight, and hydration. It is likely
 that vitamin deficiencies will occur if food intake is severely limited for a protracted period;
 assess FBC, iron, B12, and folate.
- Risk assess in line with national guidance for venous thromboembolism (VTE), given dehydration increases VTE risk, and initiate prophylactic low molecular weight heparin (LMWH) if necessary (ambulatory care centre may need to be contacted; see section 7).
 - RCOG: Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium.
- Undertake an assessment of mental health, given the negative effects of nausea and vomiting
 on wellbeing and the experience of pregnancy is often underestimated. Some people with
 poorly controlled NVP or HG become so depressed, with psychosis experienced in extreme
 cases, that a termination of pregnancy is sought to escape their overwhelming symptoms.
 - Specialist perinatal mental health services information
 - o 24/7 mental health crisis line information
 - o NICE guidance: Antenatal and postnatal mental health checklist
- Regularly follow-up to reassess symptoms and modify treatment if necessary. Consider admission for rehydration if symptoms worsen or not improve with oral antiemetics / red flags are present; contact on-call obstetrics and gynaecology team (see section 7).

Counselling

- Validate the person's experience of symptoms and do not minimise or undermine the perceived severity (Appendix 2).
- Do not falsely reassure someone with moderate to severe NVP or HG that their symptoms will dissipate by the second trimester of pregnancy; a significant number of people experience symptoms throughout the pregnancy.
- Advise that they may benefit from rest and time off work. Consider writing a sick note.
- Provide the RCOG pregnancy sickness patient information leaflet.
- Share details of <u>Pregnancy Sickness Support</u>, an organisation providing support to people experiencing NVP and HG that accepts self-referrals.



Prescribing

- Do not depend solely on non-drug management.
- The risk of inadequate nutrition and inability to take regular medications outweigh the small risks presented by antiemetic medications, all of which are considered safe in pregnancy.
- People taking critical medications, e.g., antiepileptics, biologic agents, and immunosuppressants, should be referred to the maternal medicine hub for advice / review and/or site maternal medicine clinics at the point of presentation, given the impact of missing medications can be life threatening.
- People with severe symptoms will require prescribing of multiple antiemetics concurrently.
- Optimise management of associated gastro-oesophageal reflux disease, oesophagitis, or gastritis symptoms.
- Consider avoiding medications that may contribute to NVP or HG symptoms, e.g., iron-containing preparations, utilising clinical judgement.
- Refer for ambulatory care (See section 7) in the instance of clinical dehydration, as IV fluids IV thiamine and IV antiemetics should be administered.
- Pregnant people who are taking three antiemetic medications or have persistent or recurrent symptoms despite adequate ambulatory day care treatment should be cared for as inpatients because of associated complications such as electrolyte imbalance, nutritional deficiencies, and VTE (see section 7).
- It may be possible to stop antiemetic medication at around 12–16 weeks of pregnancy, when symptoms have usually improved. However, some people continue to experience NVP or HG beyond this gestation.
- Gradually tapering the combination of antiemetics, or dose if only one agent is being used, may reduce the risk of symptoms recurring.
- NVP or HG are likely to recur in subsequent pregnancies; pre-emptive use of medication before vomiting starts can reduce the severity of disease in this instance.
- A non-medical prescriber, e.g., potentially a practice pharmacist or nurse, who are competent in the management of NVP and HG can follow people up.

4. PRACTICE POINTS FOR SECONDARY CARE (INPATIENT MANAGEMENT)

- Review risks and consider prescribing LMWH as per local guideline.
- Refer to the flowchart for an overview of inpatient management.
 - Appendix 3. Summary for ambulatory care
 - Appendix 4. Summary for emergency department staff
 - Appendix 5. Summary for inpatient care
- Refer to section 2 for antiemetic medication guidance, and section 5 for information regarding risk of medication in pregnancy.



- Levels of ketones should not be used to inform clinical decision making about treatments or hydration status.
- Dextrose-containing solutions can precipitate Wernicke's encephalopathy in thiamine-deficient states; hence they should be avoided. High doses of thiamine should be given to prevent Wernicke's encephalopathy, e.g. thiamine 250mg IV once daily for 3 days or Pabrinex given in line with local guidance. Dextrose containing fluids are appropriate for nausea and vomiting in the third trimester to prevent and treat starvation ketosis.
- Ensure suitable parental potassium supplementation occurs [see Appendix 6].
- Refer to dieticians for input in severe cases or in the context of significant weight loss (5% of pre-pregnancy body weight). The nutrition team maybe required for advice regarding the need for nasogastric or nasojejunal administration of feeds / parental nutrition in extreme cases of HG. Please discuss plan with input from maternal medicine team.
- Corticosteroids should be reserved for cases where standard therapies have failed; when initiated they should be prescribed in addition to previously started effective antiemetics. Decision to be made by senior obstetrician or maternal medicine team.
 - Consider hydrocortisone 100 mg twice daily IV, converted to prednisolone 40–50 mg orally daily once clinical improvement occurs, with the dose gradually tapered by 5-10 mg per week until the lowest maintenance dose that controls the symptoms is reached.
 - Pregnant person taking corticosteroids should have their blood pressure regularly monitored and be screened for gestational diabetes mellitus with glucose tolerance test (refer to NICE guidance: Diabetes in pregnancy).
 - o If no improvement occurs with corticosteroids within one week of commencing treatment then discuss with maternal medicine team.
- · Discharge should only occur once
 - o appropriate antiemetic therapy has been tolerated,
 - adequate oral nutrition and hydration has been tolerated,
 - o management of concurrent conditions is complete.
- At the time of discharge, it is essential that advice is given to continue with antiemetics where appropriate and that how to access further care if described.
- People with severe NVP or HG who have continued symptoms into the late second or third trimester should be offered serial scans to monitor fetal growth.
- Practitioners should carry out a full assessment of both physical and mental health status during the pregnancy and refer for psychological support if necessary.
- Information about support groups should be provided to anyone admitted with NVP or HG.
- People with previous HG should be advised that there is a risk of recurrence in future pregnancies. Early use of lifestyle/dietary modifications and antiemetics that were useful in the index pregnancy is advisable to reduce the risk of NVP and HG in any other pregnancies.



5. MEDICATION RISK IN PREGNANCY

Refer to the <u>UK Teratology Information Service</u>, for evidence-based safety information about medication, vaccine, chemical and radiological exposures in pregnancy.

It is important to complete an individual risk assessment for pregnant people you are considering prescribing for, and to apply the principles of prescribing during pregnancy when considering available information and making treatment decisions. Check to see if a risk assessment has already been completed.

When balancing risks, note that untreated or inadequately treated severe or chronic nausea and vomiting can have adverse effects on the mother and baby.

Ondansetron

Despite concerns about orofacial clefting with ondansetron use in the first trimester, there is evidence that ondansetron use is linked to only a very small increase in absolute risk (Figure 1. and Figure 2.).

The use of ondansetron should not be discouraged if first line antiemetics are ineffective, and the pregnant person can be reassured (potentially utilising the visual risk summary) that the increased risk of orofacial clefting associated with ondansetron use is very small. This very small increase in risk of orofacial clefting should be balanced against the risks of poorly managed NVP or HG.




Figure 1. Rate of orofacial clefts in non-exposed pregnancies- 11 per 10,000




Figure 2. Rate of orofacial clefts in ondansetron-exposed pregnancies- 14 per 10,000



6. CONSIDERATION OF TERMINATION OF PREGNANCY

All treatment options, including antiemetics, corticosteroids, enteral tube and parenteral feeding, and correction of electrolyte or metabolic disturbances should be considered before deciding that the only option is termination of pregnancy.

A decision to terminate a pregnancy needs to be multidisciplinary. Psychiatric opinion should be sought if there are concerns regarding mental health. In the instance NVP or HG treatment failure is the reason for termination of pregnancy, this should be clearly documented.

Any pregnant person consideration termination of pregnancy because of NVP or HG should be offered counselling before and after a decision of pregnancy termination is made.

7. HOW TO REFER FOR SPECIALIST SUPPORT / AMBULATORY CARE

Princess Royal Hospital	uhsussex.sussexmmc@nhs.net / on call gynaecology			
	registrar via switchboard 01444 441881			
Royal Sussex County Hospital	<u>uhsussex.sussexmmc@nhs.net</u> / on call gynaecology			
	registrar via switchboard 01273 696955			
Conquest Hospital & Eastbourne	esht.maternal-medicine@nhs.net 0300 131 4480			
DGH	(early pregnancy)			
St Richards Hospital, Chichester	uhsussex.srhmaternalmedicine@nhs.net on call			
	gynaecology registrar via switchboard 01243 788122			
Worthing Hospital	uhsussex.wor-mmc@nhs.net / on call gynaecology			
registrar via switchboard 01903 205111				
Maternal Medicine Hub helpline (Sussex-wide support): uhsussex.smmchelpline@nhs.net				

8. USEFUL RESOURCES AND SIGNPOSTING INFORMATION

- The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum
- RCOG pregnancy sickness patient information leaflet
- <u>Pregnancy Sickness Support</u>, an organisation providing support to people experiencing NVP and HG that accepts self-referrals.
- Pregnancy Sickness Support information about treatments for NVP and HG
- <u>UK Teratology Information Service</u>, for evidence-based safety information about medication, vaccine, chemical and radiological exposures in pregnancy.
- Specialist Pharmacy Service: Nausea and Vomiting: treatment during pregnancy
- Specialist Pharmacy Service: Assessing risk and informing the risk versus benefit decision for medicines in pregnancy
- HER Foundation hyperemesis awareness, support, and research



APPENDIX 1. SUMMARY FOR GENERAL PRACTITIONERS

The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum

Note PUQE score available in APPENDIX 2.

Vai. Summary for General Practitioners

Why is the active management of nausea and vomiting of pregnancy (NVP)/ hyperemesis gravidarum (HG) important?

- NVP/ HG is associated with serious health consequences for both mother and baby
- Patients with NVP/HG often present to primary care as onset of symptoms occur prior to their pregnancy being booked by a midwife
- Patients are likely to have tried non-pharmacological options prior to presenting thus they
 may have severe disease at first presentation to primary care


Royal College of Obstetricians & Gynaecologists



Practice points for general practitioners:

- · Validate patients' symptoms
- There are safety and efficacy data for first line antiemetic therapy including anti (H1) histamines, phenothiazines and doxylamine/pyridoxine and they should be prescribed when required for the management of NVP/HG
- In patients with severe disease multiple antiemetics prescribed together will be required
- Ketonuria is not an indicator of dehydration and should not be used to assess severity of NVP/HG
- · Guidance for referral to secondary care is included in the algorithm below
- NVP/HG is likely to recur in subsequent pregnancies and pre-emptive use of medication can reduce severity of disease future pregnancies
- · An assessment of mental as well as physical is important

Recommended simplified management algorithm for management of NVP/HG in primary care (for detailed algorithm see appendix Vaii):





APPENDIX 2. SUMMARY FOR MANAGEMENT IN GENERAL PRACTICE

Vaii. Management of Nausea and Vomiting of Pregnancy (NVP)/ Hyperemesis Gravidarum (HG) in General Practice

	Initial assessment							
	History: Previous history of NVP/HG Ptyalism (hypersalivation) Weight loss Poor oral intake Effect on quality of life Effect on mental health/mood Consider other causes in those with: Abdominal pain Urinary symptoms Infective symptoms Possible drug cause Chronic H. pylori infection Examination: Observations: Respiratory railly Resp	tion: dration	Royal College of Obstetricians & Gynaecologists GPCPC Investigations: Urine dipstick +/- MSU					
	2.00	Document: PUQE so	core /15 Weight kg					
	onset of nausea and/or vomiting in early pregnancy with no other cause is identified HG: HG: How lore sick to y	last 24 hours: ng have you felt nauseated or your stomach for? any times have you vomited?	Not at ≤1h 2-3hrs 4-6hrs >6hrs all [1] r[2] [3] [4] [5] 0x [1] 1-2x 3-4x 5-6x ≥7x					
		any times have you had g or dry heaves?	[2] [3] [4] [5] 0x [1] 1-2x 3-4x 5-6x ≥7x [2] [3] [4] [5]					
		Management						
PUQE score 3-12 and no complications Manage in community Antiemetic therapy reassure re safety of all guideline-recommended antiemetics Support and reassure Encourage oral hydration Offer dietary advice eat little and often to prevent an empty stomach Mental health assessment +/- referral to perinatal mental health services where required		Either: PUQE score ≥ 13 with no complications Inability to tolerate oral intake Community measures failed	Any red flag: Any PUQE score + complications Inability to tolerate oral intake Unresponsive to outpatient management Clinical dehydration Weight loss >5% body weight Confirmed or suspected co-morbidity e.g. UII or diabetes mellitus Co-morbidity and unable to take medications e.g. epilepsy, diabetes mellitus, HIV, hypoadrenalism and psychiatric disorders					
I I I	Reassess at 24-72 hours	Refer for ambulatory	Concerns regarding mental health					
 _	Improving Minimal/no improvement : Add 2**/3** antiemetic Refer for impatient management if red flags	daycare management	Refer for inpatient management					
	Antiemetic therapy		Other considerations					
	1st line Doxylamine and pyridoxine 20/20mg PO at night, increase to morning and 10/10mg at lunchtime if required. Cyclizine 50 mg PO, IM or IV 8 hourly Prochlorperazine 5–10 mg 6–8 hourly PO (or 3 mg buccal); 1: Promethazine 12.5–25 mg 4–8 hourly PO, IM or IV Chlorpromazine 10–25 mg 4–6 hourly PO, IM or IV		Up titration of antiemetics: Initially select a 1st line antiemetic Use combinations of drugs in women who do not respond to a single antiemetic When up titrating add drugs as opposed to replacing them Different classes of drugs may have synergistic effects and some women will require a combination of 3+ antiemetics to control symptoms					
	2nd line Metoclopramide 5–10 mg 8 hourly PO, IV/IM/SC Domperidone 10 mg 8 hourly PO; 30 mg 12 hourly PR Ondansetron 4 mg 8 hourly or 8mg 12 hourly PO; 8 mg over 3 Women taking ondansetron may require laxatives if constipation develops Prednisolone 40–50 mg daily PO, with the dose gradual maintenance dose that controls the symptoms is reached Corticosteroids should be reserved for cases where standard therapies have falled; when initiate addition to previously started antiemetics. Women taking them should have their BP monitored in the standard therapies have falled; when initiates addition to previously started antiemetics. Women taking them should have their BP monitored in the standard therapies have falled; when initiates addition to previously started antiemetics.	ly tapered until lowest	For all patients consider: Histamine type-2 receptor blockers or proton pump inhibitors if women develop GORD Both safe in pregnancy Thiamine supplementation in those with severely reduced dietary intake Laxatives if required for constipation VTE risk assessment (see RCOG risk assessment tool)					

Post-partum care, planning for future pregnancy and signposting

- Patients with severe HG are risk of PTSD if required they should be referred to appropriate service
- In future pregnancy early use of lifestyle modifications should be used
- Pre-emptive use of doxylamine and pyridoxine can be used to reduce severity of disease in subsequent pregnancy 20/20mg PO at night to be started on confirmation of positive pregnancy test and up titrated when required


















APPENDIX 3. SUMMARY FOR AMBULATORY CARE

See antiemetic therapy table for information in APPENDIX 1.

$Vb.\ Management\ of\ Nausea\ and\ Vomiting\ of\ Pregnancy\ (NVP)/\ Hyperemes is\ Gravidarum\ (HG)\ in\ the\ ambulatory\ care$

	Initial assessment			
Confirm diagnosis: NVP: onset of nausea and/or vomiting in early	Examination: Observations: Temperature	Royal College of Obstetricians & Gynaecologists Investigations: Urine dipstick +/- MSU nitrites may indicate urinary tract infection NB. Ketones are not a marker of dehydration Urea and electrolytes to assess for hypo/hyperkalaemia, hyponatraemia, kidney injury Full blood count		
pregnancy with no other cause is identified HG: Nausea and vomiting (one of which is severe) Onset <16 weeks' gestation Inability to eat and drink normally symptoms limit daily activity	Heart rate Blood pressure Respiratory rate Physical examination: Signs of dehydration Signs of malnutrition Abdominal examination Neurological signs Prescence of confusion, nystagmus or atawa should raise suspicion of Wernicke's encepholopathy Assess mental health status:			
Consider other causes in those with: Abdominal pain Urinary symptoms Infective symptoms Possible drug cause Chronic H. pylori infection		infection, raised Hb or Hct may indicate dehydration ■ Blood glucose to assess for diabetes ■ Amylase to assess for pancreatitis ■ VBG in severe cases to exclude metabolic disturbance		

Severity assessment using PUQE-24 scoring s	Document: PUQE s	core /15					
In the last 24 hours:							
How long have you felt nauseated or sick to your stomach for?	Not at all [1]	≤1hr[2]	2-3hrs [3]	4-6hrs [4]	>6hrs [5]		
How many times have you vomited?	0x [1]	1-2x [2]	3-4x [3]	5-6x [4]	≥7x [5]		
How many times have you had retching or dry heaves?	0x [1]	1-2x [2]	3-4x [3]	5-6x [4]	≥7x [5]		



Trust maybe using IV thiamine see local policy



APPENDIX 4. SUMMARY FOR EMERGENCY DEPARTMENT STAFF

		Initial assessme	nt			
Confirm diagnosis: NVP: Onset of nausea and/or vomiting in early pregnancy with no other cause is identified HG: Nausea and vomiting (one of which is severe) Inability to eat and drink normally symptoms limit daily activity Consider other causes in those with: Abdominal pain Urinary symptoms Infective symptoms Infective symptoms Possible drug cause Chronic H. pylori infection		Examination: Observations: Temperature Heart rate Blood pressure Respiratory rate Physical examination: Signs of dehydration Signs of malnutrition Abdominal examination Neurological signs Prescence of confusion, nystagmus or ataxia should raise suspicion of Wernicke's encephalopathy Assess mental health status:		Royal College of Obstetricians & Gynaecologists Investigations: Urine dipstick +/- MSU nitrites may indicate urinary tract infection NB. Ketones are not a marker of dehydration Urea and electrolytes to assess for hypo/hyperkalaemia, hyponatraemia, kidney injury Full blood count infection, raised Hb ar Hct may indicate dehydration Blood glucose to assess for diabetes Amylase to assess for pancreatitis VBG in severe cases to exclude metabolic disturbance		
In the last 24 hours: How long have you felt nauseated or sick to your st How many times have you vomited? How many times have you had retching or dry heav		Not at all [1] 0x [1] 0x [1]	≤1hr[2] 1-2x [2] 1-2x [2]	2-3hrs [3] 3-4x [3] 3-4x [3]	4-6hrs [4] 5-6x [4] 5-6x [4]	>6hrs [5] ≥7x [5] ≥7x [5]
		Management				
PUQE score 3-12 and No red flags	• Inability to	score ≥ 13 with no complications ity to tolerate oral intake nunity measures failed Send to ambulatory unit if available or treat in emergency department ibe antiemetics IM or IV ibe IV fluids: ■ 0.9% saline +20mmol Kcl over 2 hours ine supplementation either: ■ Thiamine 100mg TDS PO		complication Inability to to	ny PUQE score + mplications ability to tolerate oral intake presponsive to outpatient	
Discharge to community Start or up titrate antiemetic therapy and reassure regarding safety Encourage oral hydration Offer dietary advice eat little and often to prevent an empty stomach Provide contact number for	Prescribe Prescribe				Clinical dehy Weight loss > Confirmed or morbidity e.g.	dration -5% body weight - suspected co- UTI or diabetes mellitus - and unable to ions e.g. epilepsy, HIV,
early pregnancy unit Referral to perinatal mental health services where	•				Refer for inpatient management Pregnancy Sickness Support	
required		Reassess			HER FO	oundation
For all patients consider: Histamine type-2 receptor blockers or proton pump inhibitors if women develop GORD (safe in pregnancy) Thiamine supplementation in those with severely reduced dietary intake to prevent Wernicke's encephalopathy Laxatives if required for constipation VTE risk assessment (see RCOG risk assessment tool) Like Teratology Information Service WK Teratology Information Service						

Trust maybe using IV thiamine see local policy

APPENDIX 5. SUMMARY FOR INPATIENT CARE



Vd. Management of Nausea and Vomiting of Pregnancy (NVP)/ Hyperemesis Gravidarum (HG) as an In-patient



Initial assessment						
History: Previous history of NVP/HG Pytalism (hypersalivation) Weight loss Poor oral intake Effect on quality of life Effect on mental health/mood Consider other causes in those with: Abdominal pain Urinary symptoms Infective symptoms Possible drug cause Chronic H. pylori infection Examinatio Posservatio Respiration Physical ex Signs of Signs of Signs of Abdom Neurol	Investigations: Urine dipstick +/- MSU nitrites may indicate urinary tract infection NB. Ketones are not a marker of dehydration Urea and electrolytes to assess for hypo/hyperkalaemia, hyponatraemia, kidney injury Full blood count infection, raised Hb or Hct may indicate dehydration Blood glucose to assess for diabetes In refractory cases: Thyroid function tests Liver function tests box exclude liver disease Bone profile to monitor calcium and phosphate Amylase to exclude metabolic disturbance					
Diagnosis and severity assessme	ent Document: PU	IQE score /15 Weight kg				
Diagnosis: NVP: onset of nausea and/or vomiting in early pregnancy with no other cause is identified HG: Nausea and vomiting (one of which is severe) Onset <16 weeks' gestation Inability to eat and drink normally symptoms limit daily activity	Not at ≤1h 2-3hrs 4-6hrs >6hrs all [1] r[2] [3] [4] [5] Ox 1-2x 3-4x 5-6x ≥7x [1] [2] [3] [4] [5] Ox [1] 1-2x 3-4x 5-6x ≥7x [5] [2] [3] [4]					
Adm	nission criteria and managemen	ıt				
Admit if any of the following: Any PUQE score plus: Unresponsive to outpatient management: Clinical dehydration Inability to tolerate oral intake Weight loss >5% body weight Confirmed or suspected comorbidity e.g. UTI or diabetes mellitus Co-morbidity and unable to take medications e.g. hypoadrenalism, epilepsy, psychiatric disorder and HIV Inpatient management: Prescribe antiemetics IM or IV Prescribe on IV Prescribe antiemetics IM or IV Prescribe on IV Prescribe antiemetics IM or IV Prescribe diadiewith potassium chlorine guided by daily monitoring of electrolytes Prescribe thiamine supplementation either: Thiamine 100mg TDS PO or Pabrinex® I+II (vial of each) IV Prescribe venous thromboprophylaxis Prescribe venous thromboprophylaxis Prescribe histamine type-2 receptor blockers or proton pump inhibitors in women with GORD Undertake a mental health assessment +/- refer to mental health services Schedule ultrasound scan to confirm viability, gestational age and to assess for trophoblastic disease or multiple pregnancy Enquire regarding constipation and prescribe laxatives if required Consider enteral or parenteral nutrition in cases where all other medical therapies have failed to sufficiently manage symptoms						
Antiemetic therapy		On discharge				
Doxylamine and pyridoxine 20/20mg PO at night, increase morning and 10/10mg at lunchtime if required. Cyclizine 50 mg PO, IM or IV 8 hourly Prochlorperazine 5–10 mg 6–8 hourly PO (or 3 mg buccal); Promethazine 12.5–25 mg 4–8 hourly PO, IM or IV Chlorpromazine 10–25 mg 4–6 hourly PO, IM or IV	Up titrate antiemetic therapy and reassure regarding safety Encourage oral hydration Offer dietary advice eat little and often to prevent an empty stomach Provide contact number for early pregnancy unit					
2 nd Metoclopramide 5–10 mg 8 hourly PO, IV/IM/SC line Domperidone 10 mg 8 hourly PO; 30–60 mg daily PR	Metodopramae 5 10 mg 6 mounty 1 6,117,1117,50					
Ondansetron 4 mg 8 hourly or 8 mg 12 hourly PO; 8 mg over the standard threapies have failed; when initial addition to previously started antiemetics. Women taking ondansetron may require laxatives if constipation develops Women taking ondansetron may require laxatives if constipation develops Hydrocortisone 100mg twice daily IV; then convert to predict with the dose gradually tapered until lowest maintenance symptoms is reached Corticosteroids should be reserved for cases where standard therapies have failed; when initial addition to previously started antiemetics. Women taking them should have their BP monitors	Initially select a 1st line antiemetic Use combinations of drugs in women who do not respond to a single antiemetic When up titrating add drugs as opposed to replacing them different classes of drugs may have synergistic effects and some women will require a combination of 3+ antiemetics to control symptoms					
Post-partum care, planning for future pregnancy and signposting						

- Patients with severe HG are risk of PTSD if required they should be referred to appropriate service
- In future pregnancy early use of lifestyle modifications should be used
- Pre-emptive use of doxylamine and pyridoxine can be used to reduce severity of disease in subsequent pregnancy 20/20mg PO at night to be started on confirmation of positive pregnancy ter and up titrated when required



- Pregnancy Sickness Support
- HER Foundation
- UK Teratology Information Service





14